http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2283253-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_700ff9a01db2075489cb7ed87392dc28
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14143
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10345
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10352
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-864
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
filingDate 1998-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_671bc0ab44cb371efce5a6f56efce11c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec387407ac68e71d7cb5aaeef3bc8d77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a45712df5ef39dabb91f9f3fae66c64b
publicationDate 1998-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CA-2283253-A1
titleOfInvention Adenovirus e1-complementing cell lines
abstract A new series of helper cell lines for the complementation, amplification, and controlled attenuation of E1-deleted adenovirus are disclosed in the present invention. These cell lines are advantageous because they can complement adenovirus E1 genedeletions without production of replication competent adenovirus (RCA), thus making them safer for the large-scale production of adenovirus stock for use in human genetherapy trials. A preferred embodiment is an A549E1 cell line that contains only the Ad5 E1 DNA sequences sufficient for complementation of E1-deleted adenoviral vectors without sequences that overlap with the adenovirus vector. In another aspect, the present invention embodies methods for the production of second generation A549-E1 complementing cell lines that, in addition to producing E1, also produce proteins required for further manipulation of adenoviral vectors. A preferred embodiment is an A549E1 cell line with DNA sequences that encode a polypeptide sufficient for packaging attenuation of E1-deleted helper virus, in order to enrich for packaging of mini-adenovirus.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20180118560-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11299713-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102122117-B1
priorityDate 1997-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID10535
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID152743249
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID10535
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419521105
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID125893

Total number of triples: 30.